STOCK TITAN

[8-K] Boston Scientific Corp. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K

Boston Scientific Corporation announced that Jeffrey B. Mirviss, Executive Vice President and President, Peripheral Interventions, will retire effective December 1, 2025 and remain as a senior advisor through February 27, 2026. During the advisory period he will receive his current base salary of $705,000, prorated to the Retirement Date. The company expects to enter a Retirement Agreement providing payments and benefits materially consistent with its Executive Retirement Plan, 2025 Annual Bonus Plan and Long-Term Incentive Program and related equity awards.

Boston Scientific Corporation ha annunciato che Jeffrey B. Mirviss, Vicepresidente Esecutivo e Presidente, Interventi Periferici, si ritirerà con effetto 1 dicembre 2025 e rimarrà come senior advisor fino al 27 febbraio 2026. Durante il periodo di consulenza riceverà l'attuale salario di base di $705,000, proporzionato alla data di pensionamento. L'azienda prevede di stipulare un Retirement Agreement che preveda pagamenti e benefici sostanzialmente coerenti con il suo Executive Retirement Plan, il 2025 Annual Bonus Plan e il Long-Term Incentive Program e relativi premi azionari.

Boston Scientific Corporation anunció que Jeffrey B. Mirviss, Vicepresidente Ejecutivo y Presidente, Intervenciones Periféricas, se retirará con efecto 1 de diciembre de 2025 y permanecerá como asesor senior hasta el 27 de febrero de 2026. Durante el periodo de asesoría recibirá su salario base actual de $705,000, prorrateado hasta la Fecha de Jubilación. La empresa espera celebrar un Retirement Agreement que prevea pagos y beneficios sustancialmente consistentes con su Executive Retirement Plan, el 2025 Annual Bonus Plan y el Long-Term Incentive Program y los correspondientes premios de acciones.

Boston Scientific Corporation Jeffrey B. Mirviss가 Executive Vice President and President, Peripheral Interventions로서 2025년 12월 1일부로 은퇴하고 2026년 2월 27일까지 수석 자문으로 남아 있을 것이라고 발표했습니다. 자문 기간 동안 그는 Retirement Date까지 비례 지급되는 현재 기본급 $705,000를 받게 됩니다. 회사는 Executive Retirement Plan, 2025 Annual Bonus Plan 및 Long-Term Incentive Program 및 관련 주식 보상과 일관된 지급 및 혜택을 제공하는 Retirement Agreement를 체결할 것으로 기대합니다.

Boston Scientific Corporation a annoncé que Jeffrey B. Mirviss, vice-président exécutif et président, Interventions Périphériques, prendra sa retraite à effet 1er décembre 2025 et restera conseiller principal jusqu’au 27 février 2026. Pendant la période de conseil, il recevra son salaire de base actuel de $705,000, au prorata jusqu’à la date de retraite. L’entreprise prévoit de conclure un Retirement Agreement fournissant des paiements et des prestations substantiellement conformes à son Executive Retirement Plan, au 2025 Annual Bonus Plan et au Long-Term Incentive Program et aux actions associées.

Boston Scientific Corporation gab bekannt, dass Jeffrey B. Mirviss, Executive Vice President and President, Peripheral Interventions, mit Wirkung zum 1. Dezember 2025 in den Ruhestand treten wird und bis zum 27. Februar 2026 als Senior Advisor tätig bleibt. Während des Beratungszeitraums erhält er sein aktuelles Grundgehalt von $705,000, anteilig bis zum Rentenbeginn. Das Unternehmen erwartet, eine Retirement Agreement abzuschließen, das Zahlungen und Leistungen vorsieht, die wesentlicheä mit seinem Executive Retirement Plan, dem 2025 Annual Bonus Plan und dem Long-Term Incentive Program sowie den zugehörigen Aktienprämien übereinstimmen.

Boston Scientific Corporation أعلنت أن Jeffrey B. Mirviss، نائب الرئيس التنفيذي والرئيس، Interventions périphériques، سيتقاعد اعتبارًا من 1 ديسمبر 2025 وسيبقى مستشارًا كبيرًا حتى 27 فبراير 2026. خلال فترة الاستشارة سيستلم راتبه الأساسي الحالي البالغ $705,000، بنسبة حتى تاريخ التقاعد. تتوقع الشركة الدخول في Retirement Agreement يوفر المدفوعات والمزايا بما يتوافق جوهريًا مع خطتها للتقاعد التنفيذي وخطة المكافأة السنوية 2025 وبرنامج الحوافز الطويلة الأجل وسبل الأسهم المرتبطة.

Boston Scientific Corporation 宣布,Jeffrey B. Mirviss,执行副总裁兼总裁,外周介入部,将于 2025年12月1日 正式退休,并将以高级顾问身份继续任职至 2026年2月27日。在顾问期间,他将按退休日期按比例获得其当前基本薪资 $705,000。公司预计将签署 Retirement Agreement,提供与其 Executive Retirement Plan、2025 年奖金计划和长期激励计划及相关股权奖励实质性一致的支付与福利。

Positive
  • Planned transition with advisory overlap through February 27, 2026 supports continuity
  • Retirement package aligns with existing executive plans, reducing risk of bespoke costly arrangements
  • Base salary maintained at $705,000 and prorated during advisory period
Negative
  • Potential short-term leadership gap if a successor is not named before December 1, 2025
  • Near-term compensation expense from prorated salary and continued benefits during advisory period

Insights

Senior leadership transition is orderly with a short advisory overlap.

The announced retirement sets a clear timeline: active role until December 1, 2025 with advisory support through February 27, 2026, which reduces near-term operational disruption in Peripheral Interventions. The company commits to a standard retirement agreement tied to existing executive plans rather than bespoke severance terms.

This arrangement preserves institutional knowledge during handover but will modestly increase near-term compensation expense, specifically the prorated $705,000 base pay and continuation of benefit frameworks; monitor successor appointment timing and any disclosed transitional responsibilities over the next three months.

Boston Scientific Corporation ha annunciato che Jeffrey B. Mirviss, Vicepresidente Esecutivo e Presidente, Interventi Periferici, si ritirerà con effetto 1 dicembre 2025 e rimarrà come senior advisor fino al 27 febbraio 2026. Durante il periodo di consulenza riceverà l'attuale salario di base di $705,000, proporzionato alla data di pensionamento. L'azienda prevede di stipulare un Retirement Agreement che preveda pagamenti e benefici sostanzialmente coerenti con il suo Executive Retirement Plan, il 2025 Annual Bonus Plan e il Long-Term Incentive Program e relativi premi azionari.

Boston Scientific Corporation anunció que Jeffrey B. Mirviss, Vicepresidente Ejecutivo y Presidente, Intervenciones Periféricas, se retirará con efecto 1 de diciembre de 2025 y permanecerá como asesor senior hasta el 27 de febrero de 2026. Durante el periodo de asesoría recibirá su salario base actual de $705,000, prorrateado hasta la Fecha de Jubilación. La empresa espera celebrar un Retirement Agreement que prevea pagos y beneficios sustancialmente consistentes con su Executive Retirement Plan, el 2025 Annual Bonus Plan y el Long-Term Incentive Program y los correspondientes premios de acciones.

Boston Scientific Corporation Jeffrey B. Mirviss가 Executive Vice President and President, Peripheral Interventions로서 2025년 12월 1일부로 은퇴하고 2026년 2월 27일까지 수석 자문으로 남아 있을 것이라고 발표했습니다. 자문 기간 동안 그는 Retirement Date까지 비례 지급되는 현재 기본급 $705,000를 받게 됩니다. 회사는 Executive Retirement Plan, 2025 Annual Bonus Plan 및 Long-Term Incentive Program 및 관련 주식 보상과 일관된 지급 및 혜택을 제공하는 Retirement Agreement를 체결할 것으로 기대합니다.

Boston Scientific Corporation a annoncé que Jeffrey B. Mirviss, vice-président exécutif et président, Interventions Périphériques, prendra sa retraite à effet 1er décembre 2025 et restera conseiller principal jusqu’au 27 février 2026. Pendant la période de conseil, il recevra son salaire de base actuel de $705,000, au prorata jusqu’à la date de retraite. L’entreprise prévoit de conclure un Retirement Agreement fournissant des paiements et des prestations substantiellement conformes à son Executive Retirement Plan, au 2025 Annual Bonus Plan et au Long-Term Incentive Program et aux actions associées.

Boston Scientific Corporation gab bekannt, dass Jeffrey B. Mirviss, Executive Vice President and President, Peripheral Interventions, mit Wirkung zum 1. Dezember 2025 in den Ruhestand treten wird und bis zum 27. Februar 2026 als Senior Advisor tätig bleibt. Während des Beratungszeitraums erhält er sein aktuelles Grundgehalt von $705,000, anteilig bis zum Rentenbeginn. Das Unternehmen erwartet, eine Retirement Agreement abzuschließen, das Zahlungen und Leistungen vorsieht, die wesentlicheä mit seinem Executive Retirement Plan, dem 2025 Annual Bonus Plan und dem Long-Term Incentive Program sowie den zugehörigen Aktienprämien übereinstimmen.

0000885725false00008857252025-08-292025-08-290000885725us-gaap:CommonStockMember2025-08-292025-08-290000885725bsx:SeniorNotedue2027Member2025-08-292025-08-29


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________________

FORM 8-K
CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
_____________________________________________________________________

Date of Report (Date of earliest event reported): August 29, 2025

BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
Delaware1-1108304-2695240
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification No.)

    300 Boston Scientific Way, Marlborough, Massachusetts                 01752-1234
    (Address of principal executive offices)                           (Zip Code)

(508) 683-4000
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.01 par value per shareBSXNew York Stock Exchange
0.625% Senior Notes due 2027BSX27New York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company   
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   



Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers.

On August 29, 2025, Jeffrey B. Mirviss informed Boston Scientific Corporation (the “Company”) that he has decided to retire from his role as Executive Vice President and President, Peripheral Interventions effective as of December 1, 2025.

Mr. Mirviss is expected to remain with the Company as a senior advisor from such time through February 27, 2026 (such date, or any earlier date, the “Retirement Date”). As a senior advisor, Mr. Mirviss will receive a base salary at his current annual base salary of $705,000, prorated through the Retirement Date.

The Company expects to enter into a Retirement Agreement with Mr. Mirviss effective as of the Retirement Date, pursuant to which Mr. Mirviss will be entitled to payments and benefits that are materially consistent with those Mr. Mirviss is entitled to under, and subject to the terms and conditions of, the Company’s Executive Retirement Plan, 2025 Annual Bonus Plan and Long-Term Incentive Program and equity awards granted thereunder, respectively, each as previously filed with the U.S. Securities and Exchange Commission.




SIGNATURE


Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
                        
                                
Date:September 4, 2025BOSTON SCIENTIFIC CORPORATION
By:/s/ Susan Thompson
Susan Thompson
Vice President, Chief Corporate Counsel and Assistant Secretary


FAQ

What did Boston Scientific (BSX) announce about Jeffrey B. Mirviss?

The company announced Mr. Mirviss will retire as EVP and President, Peripheral Interventions effective December 1, 2025 and serve as senior advisor through February 27, 2026.

How much will Jeffrey Mirviss be paid during the advisory period?

He will receive his current base salary of $705,000, prorated through the Retirement Date.

Will Mirviss receive additional retirement benefits?

The company expects a Retirement Agreement providing payments and benefits materially consistent with the Executive Retirement Plan, 2025 Annual Bonus Plan, and Long-Term Incentive Program.

Is the retirement immediate or will there be a handover?

The retirement is effective December 1, 2025, but Mr. Mirviss will remain as a senior advisor through February 27, 2026 to support transition.

Does the filing disclose a successor for the role?

No; the filing does not name a successor or provide timing for a replacement.
Boston Scien Cp

NYSE:BSX

BSX Rankings

BSX Latest News

BSX Latest SEC Filings

BSX Stock Data

148.03B
1.48B
0.19%
93.65%
1.28%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MARLBOROUGH